|
1
|
Cui W, Rocconi RP, Thota R, Anderson RA,
Bruinooge SS, Comstock IA, Denduluri N, Gassman A, Gralow J, Hutt
KJ, et al: Measuring ovarian toxicity in clinical trials: An
American society of clinical oncology research statement. Lancet
Oncol. 24:e415–e423. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Godbole N, Quinn A, Carrion F, Pelosi E
and Salomon C: Extracellular vesicles as a potential delivery
platform for CRISPR-Cas based therapy in epithelial ovarian cancer.
Semin Cancer Biol. 96:64–81. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rayment I: Kinesin and myosin: Molecular
motors with similar engines. Structure. 4:501–504. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhong M, Gong L, Li N, Guan H, Gong K,
Zhong Y, Zhu E, Wang X, Jiang S, Li J, et al: Pan-cancer analysis
of kinesin family members with potential implications in prognosis
and immunological role in human cancer. Front Oncol.
13:11798972023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qiao S, Jiang Y, Li N and Zhu X: The
kinesin light chain-2, a target of mRNA stabilizing protein HuR,
inhibits p53 protein phosphorylation to promote radioresistance in
NSCLC. Thorac Cancer. 14:1440–1450. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baek JH, Yun HS, Kim JY, Lee J, Lee YJ,
Lee CW, Song JY, Ahn J, Park JK, Kim JS, et al: Kinesin light chain
4 as a new target for lung cancer chemoresistance via targeted
inhibition of checkpoint kinases in the DNA repair network. Cell
Death Dis. 11:3982020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baek JH, Lee J, Yun HS, Lee CW, Song JY,
Um HD, Park JK, Park IC, Kim JS, Kim EH and Hwang SG: Kinesin light
chain-4 depletion induces apoptosis of radioresistant cancer cells
by mitochondrial dysfunction via calcium ion influx. Cell Death
Dis. 9:4962018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Feng S, Luo S, Ji C and Shi J: miR-29c-3p
regulates proliferation and migration in ovarian cancer by
targeting KIF4A. World J Surg Oncol. 18:3152020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sheng N, Xu YZ, Xi QH, Jiang HY, Wang CY,
Zhang Y and Ye Q: Overexpression of KIF2A is suppressed by miR-206
and associated with poor prognosis in ovarian cancer. Cell Physiol
Biochem. 50:810–822. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li H, Zhang W, Sun X, Chen J, Li Y, Niu C,
Xu B and Zhang Y: Overexpression of kinesin family member 20A is
associated with unfavorable clinical outcome and tumor progression
in epithelial ovarian cancer. Cancer Manag Res. 10:3433–3450. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kawai Y, Shibata K, Sakata J, Suzuki S,
Utsumi F, Niimi K, Sekiya R, Senga T, Kikkawa F and Kajiyama H:
KIF20A expression as a prognostic indicator and its possible
involvement in the proliferation of ovarian clear-cell carcinoma
cells. Oncol Rep. 40:195–205. 2018.PubMed/NCBI
|
|
12
|
Han X, Yang L, Tian H and Ji Y: Machine
learning developed a PI3K/Akt pathway-related signature for
predicting prognosis and drug sensitivity in ovarian cancer. Aging
(Albany NY). 15:11162–11183. 2023.PubMed/NCBI
|
|
13
|
Konjikusic MJ, Gray RS and Wallingford JB:
The developmental biology of kinesins. Dev Biol. 469:26–36. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu L, Wei J and Liu P: Attacking the
PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment
in human cancer. Semin Cancer Biol. 85:69–94. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li H, Zeng J and Shen K: PI3K/AKT/mTOR
signaling pathway as a therapeutic target for ovarian cancer. Arch
Gynecol Obstet. 290:1067–1078. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ediriweera MK, Tennekoon KH and Samarakoon
SR: Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer:
Biological and therapeutic significance. Semin Cancer Biol.
59:147–160. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yoshihara K, Tajima A, Komata D, Yamamoto
T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K,
et al: Gene expression profiling of advanced-stage serous ovarian
cancers distinguishes novel subclasses and implicates ZEB2 in tumor
progression and prognosis. Cancer Sci. 100:1421–1428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mok SC, Bonome T, Vathipadiekal V, Bell A,
Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, et al: A
gene signature predictive for outcome in advanced ovarian cancer
identifies a survival factor: Microfibril-associated glycoprotein
2. Cancer Cell. 16:521–532. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
O'Shea AS: Clinical staging of ovarian
cancer. Methods Mol Biol. 2424:3–10. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dixon JR Jr: The International conference
on harmonization good clinical practice guideline. Qual Assur.
6:65–74. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou Y, Zhou B, Pache L, Chang M,
Khodabakhshi AH, Tanaseichuk O, Benner C and Chanda SK: Metascape
provides a biologist-oriented resource for the analysis of
systems-level datasets. Nat Commun. 10:15232019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tjioe M, Shukla S, Vaidya R, Troitskaia A,
Bookwalter CS, Trybus KM, Chemla YR and Selvin PR: Multiple
kinesins induce tension for smooth cargo transport. Elife.
8:e509742019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cong S, Fu Y, Zhao X, Guo Q, Liang T, Wu
D, Wang J and Zhang G: KIF26B and CREB3L1 derived from immunoscore
could inhibit the progression of ovarian cancer. J Immunol Res.
2024:48179242024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu X, Gong H and Huang K: Oncogenic role
of kinesin proteins and targeting kinesin therapy. Cancer Sci.
104:651–656. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li X, Huang W, Huang W, Wei T, Zhu W, Chen
G and Zhang J: Kinesin family members KIF2C/4A/10/11/14/18B/20A/23
predict poor prognosis and promote cell proliferation in
hepatocellular carcinoma. Am J Transl Res. 12:1614–1639.
2020.PubMed/NCBI
|
|
27
|
Liang LY and Li GS: The Roles of KIFC1 in
the development of osteosarcoma: Characterization of potential
therapeutic targets. Comput Math Methods Med. 2022:50391342022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang G, Hou S, Li S, Wang Y and Cui W:
Role of STAT3 in cancer cell epithelial-mesenchymal transition
(Review). Int J Oncol. 64:482024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Śliwa A, Szczerba A, Pięta PP, Białas P,
Lorek J, Nowak-Markwitz E and Jankowska A: A recipe for successful
metastasis: Transition and migratory modes of ovarian cancer cells.
Cancers (Basel). 16:7832024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Szczerba A, Śliwa A, Pieta PP and
Jankowska A: The role of circulating tumor cells in ovarian cancer
dissemination. Cancers(Basel). 14:60302022.PubMed/NCBI
|
|
31
|
Kuivaniemi H and Tromp G: Type III
collagen (COL3A1): Gene and protein structure, tissue distribution,
and associated diseases. Gene. 707:151–171. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang H, Ding C, Li Y, Xing C, Wang S, Yu
Z, Chen L, Li P and Dai M: Data mining-based study of collagen type
III alpha 1 (COL3A1) prognostic value and immune exploration in
pan-cancer. Bioengineered. 12:3634–3646. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Januchowski R, Świerczewska M, Sterzyńska
K, Wojtowicz K, Nowicki M and Zabel M: Increased expression of
several collagen genes is associated with drug resistance in
ovarian cancer cell lines. J Cancer. 7:1295–1310. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu W, Li Z, Zhu X, Xu R and Xu Y: miR-29
family inhibits resistance to methotrexate and promotes cell
apoptosis by targeting COL3A1 and MCL1 in osteosarcoma. Med Sci
Monit. 24:8812–8821. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang L, Sun Y, Guo Z and Liu H: COL3A1
overexpression associates with poor prognosis and cisplatin
resistance in lung cancer. Balkan Med J. 39:393–400. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gao YF, Zhu T, Chen J, Liu L and Ouyang R:
Knockdown of collagen α-1(III) inhibits glioma cell proliferation
and migration and is regulated by miR128-3p. Oncol Lett.
16:1917–1923. 2018.PubMed/NCBI
|
|
37
|
Ozsolak F and Milos PM: RNA sequencing:
Advances, challenges and opportunities. Nat Rev Genet. 12:87–98.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang H, Xu YH and Guo Y: Novel prognostic
marker TGFBI affects the migration and invasion function of ovarian
cancer cells and activates the integrin αvβ3-PI3K-Akt signaling
pathway. J Ovarian Res. 17:502024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li GW, Jin YP, Qiu JP and Lu XF: ITGB2
fosters the cancerous characteristics of ovarian cancer cells
through its role in mitochondrial glycolysis transformation. Aging
(Albany NY). 16:3007–3020. 2024.PubMed/NCBI
|
|
40
|
Ma S, Wang J, Cui Z, Yang X, Cui X, Li X
and Zhao L: HIF-2α-dependent TGFBI promotes ovarian cancer
chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis
and facilitate DNA repair process. Sci Rep. 14:38702024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li W, Zhang K, Wang W, Liu Y, Huang J,
Zheng M, Li L, Zhang X, Xu M, Chen G, et al: Combined inhibition of
HER2 and VEGFR synergistically improves therapeutic efficacy via
PI3K-AKT pathway in advanced ovarian cancer. J Exp Clin Cancer Res.
43:562024. View Article : Google Scholar : PubMed/NCBI
|
